Belgian Society of Medical Oncology (BSMO) meeting, 2024

‍

Authors

Laura Polastro ^[1,2], Maximilien Autheman ³, Arlindo Ferreira ^[3,4], Juliette Fanton d’Andon ³, Alice Wolfromm ^[1,2], Alain Hendlisz ^[1,2], Nieves Martinez Chanza ^,[1,2], Laurence Caravella ^[1,2], Evandro de Azambuja ^[1,2].

‍

Affiliation

1. Institut Jules Bordet-Hôpitaux Universitaires de Bruxelles ; 2. Université Libre de Bruxelles ; 3. Resilience ; 4. Universidade Catolica Portuguesa, Lisbonne, Portugal.

‍

Introduction

The European Society for Medical Oncology (ESMO) recommends Remote Patient Monitoring (RPM) in oncology for patients undergoing anti-cancer treatment, given the clinical and organizational benefits^[1-4] concerning:

• Symptom control,
• Quality of life,
• Reduction in the number of hospitalizations,
• Prolongation of overall survival.

The Resilience PRO medical device (Class IIa) offers a patient interface for symptom reporting and a healthcare professional interface for alert monitoring. Personalized resources are also provided to patients via the mobile application.

As of December 2023, Resilience is deployed in 61 centers and monitors 4,240 patients across Europe. This study evaluates the feasibility of implementing Resilience in routine clinical care at the Jules Bordet Institute.

Poster presented at the 2024BSMO congress (Belgian Society of Medical Oncology).

‍

Sources

1. Mir O, Ferrua M, Fourcade A, et al. Digital remotemonitoring plus usual care versus usual carein patients treated with oral anticancer agents:the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.

2. Basch E, Schrag D, Henson S, et al. Effect ofElectronic Symptom Monitoring on Patient-Reported Outcomes Among Patients WithMetastatic Cancer: A Randomized ClinicalTrial. JAMA. 2022;327(24):2413-2422.

3. Basch E, Deal AM, Kris MG, et al. SymptomMonitoring With Patient-Reported OutcomesDuring Routine Cancer Treatment: A RandomizedControlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.

4. Basch E, Deal AM, Dueck AC, et al. OverallSurvival Results of a Trial Assessing Patient-Reported Outcomes for Symptom MonitoringDuring Routine Cancer Treatment. JAMA.2017;318(2):197-198